TABLE 2.
Distribution of high-risk HPV genotypes among women undergoing self-sampling in the CSi study, compared with that for routinely screened women participating in the Horizon study, by use of the CLART assay
| High-risk HPV genotype | Total no. (prevalence [%]) of infectionsa in the following study: |
|
|---|---|---|
| CSib (n = 4,801) | Horizonc (n = 3,336) | |
| HPV16 | 138 (2.9) | 150 (4.5) |
| HPV18 | 29 (0.6) | 57 (1.7) |
| HPV31 | 76 (1.6) | 95 (2.8) |
| HPV33 | 30 (0.6) | 67 (2.0) |
| HPV35 | 46 (1.0) | 42 (1.3) |
| HPV39 | 18 (0.4) | 20 (0.6) |
| HPV45 | 23 (0.5) | 39 (1.2) |
| HPV51 | 97 (2.0) | 79 (2.4) |
| HPV52 | 74 (1.5) | 107 (3.2) |
| HPV56 | 19 (0.4) | 35 (1.0) |
| HPV58 | 52 (1.1) | 91 (2.7) |
| HPV59 | 42 (0.9) | 49 (1.5) |
| HPV68 | 5 (0.1) | 55 (1.6) |
a
The numbers of infections with the different genotypes do not add up to the total numbers of women with high-risk HPV infections (544 in the CSi study and 618 in the Horizon study) because some women had multiple HPV infections.
b
Samples from 4,824 women were tested by the CLART assay. Of these, 4,801 (99.5%) had valid results.
c
Samples from 3,347 women were tested by the CLART assay, and 3,336 (99.7%) had valid results.